ATXS - NASDAQ
Astria Therapeutics, Inc.
$12.58
+0.0000%Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
At a Glance
Live Snapshotatxs
Selling, General and Administrative Expenses
Last Annual Value
35.25M
3-Year CAGR
34%
5-Year CAGR
32%
10-Year CAGR
19%
Astria Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Astria Therapeutics, Inc. NASDAQ:ATXS | 35.25M | 11.1% | 18.9% | 13.3% | |
 Iovance Biotherapeutics, Inc. NASDAQ:IOVA | 152.32M | 12.5% | 12.7% | 24.4% | |
 Erasca, Inc. NASDAQ:ERAS | 38.55M | 0.7% | 11.3% | N/A | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 24.18M | 35.6% | 60.6% | N/A | |
 MBX Biosciences, Inc. Common Stock NASDAQ:MBX | 18.90M | 40.7% | N/A | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 0.00 | N/A | N/A | N/A | |
 Arvinas, Inc. NASDAQ:ARVN | 89.40M | -3.8% | 7.7% | 39.5% | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 120.59M | 17.1% | 33.0% | N/A | |
 Ginkgo Bioworks Holdings, Inc. NYSE:DNA | 183.29M | -21.9% | -26.6% | N/A | |
 MeiraGTx Holdings plc NASDAQ:MGTX | 52.90M | 3.8% | 3.9% | 24.3% |
Astria Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ATXS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.